Enanta Pharmaceuticals, Inc. (ENTA)
NASDAQ·Healthcare·Biotechnology
$13.71
+3.20%
Mkt Cap $309.01M
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q1 2026 Feb 9, 2026 | $15.90M | $18.61M | +17.04% | -$0.54 | -$0.42 | +22.22% | — | — |
| Q4 2025 Nov 17, 2025 | $15.97M | $15.13M | -5.29% | -$1.13 | -$0.87 | +23.01% | — | — |
| Q3 2025 Aug 11, 2025 | $15.97M | $18.31M | +14.67% | -$1.25 | -$0.85 | +32.00% | — | — |
| Q2 2025 May 12, 2025 | $15.96M | $14.93M | -6.48% | -$1.04 | -$1.06 | -1.92% | — | — |
| Q1 2025 Feb 10, 2025 | $17.25M | $16.96M | -1.68% | -$1.16 | -$1.05 | +9.48% | — | — |
| Q4 2024 Nov 25, 2024 | $17.93M | $67.64M | +277.22% | -$1.16 | -$1.36 | -17.24% | — | — |
| Q3 2024 Aug 5, 2024 | $17.80M | $17.97M | +0.96% | -$1.49 | -$1.07 | +28.19% | — | — |
| Q2 2024 May 6, 2024 | $16.52M | $17.05M | +3.23% | -$1.26 | -$1.47 | -16.67% | — | — |
| Q1 2024 Feb 7, 2024 | $21.95M | $18.00M | -17.98% | -$1.18 | -$1.58 | -33.90% | — | — |
| Q4 2023 Nov 20, 2023 | $20.60M | $18.93M | -8.10% | -$2.11 | -$1.33 | +36.97% | — | — |
| Q3 2023 Aug 7, 2023 | $20.66M | $18.89M | -8.56% | -$2.38 | -$1.86 | +21.85% | — | — |
| Q2 2023 May 8, 2023 | $19.18M | $17.80M | -7.22% | -$1.91 | -$1.79 | +6.28% | — | — |
| Q1 2023 Feb 7, 2023 | $23.55M | $23.59M | +0.14% | -$1.52 | -$1.39 | +8.55% | — | — |
| Q4 2022 Nov 21, 2022 | $23.13M | $20.32M | -12.16% | -$1.37 | -$1.27 | +7.30% | — | — |
| Q3 2022 Aug 8, 2022 | $20.65M | $19.48M | -5.68% | -$1.36 | -$1.53 | -12.50% | — | — |
| Q2 2022 May 9, 2022 | $20.67M | $18.72M | -9.44% | -$1.43 | -$1.63 | -13.99% | — | — |
| Q1 2022 Feb 8, 2022 | $27.37M | $27.65M | +1.03% | -$1.13 | -$1.48 | -30.97% | — | — |
| Q4 2021 Nov 22, 2021 | $27.39M | $23.57M | -13.93% | -$1.31 | -$1.22 | +6.87% | — | — |
| Q3 2021 Aug 5, 2021 | $21.86M | $21.62M | -1.08% | -$1.41 | -$1.19 | +15.60% | — | — |
| Q2 2021 May 6, 2021 | $17.87M | $20.13M | +12.64% | -$0.94 | -$1.09 | -15.96% | — | — |